Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,462 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adult Solid Neoplasm Clear all
Terminated Phase 1 Interventional

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors

NCT05601219
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
ADA-011, PD(L)-1 inhibitor
Drug
Lead sponsor
Adanate, Inc
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Scottsdale, Arizona • Orlando, Florida • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 28, 2026, 11:09 PM EDT
Terminated Not applicable Interventional

Quantitative MRI in Assessing Disease in Patients With Brain Tumors

NCT02269111
View directory record Official record
Conditions
Tumors Metastatic to Brain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
diffusion-weighted magnetic resonance imaging, chemical exchange saturation transfer magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging, dynamic susceptibility contrast-enhanced magnetic resonance imaging
Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Oct 28, 2026, 11:09 PM EDT
Completed Phase 3 Interventional Results available

Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

NCT00489411
View directory record Official record
Conditions
Neurotoxicity, Pain, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
duloxetine hydrochloride, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
25 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
475
States / cities
Antioch, California • Berkeley, California • Burlingame, California + 328 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 28, 2026, 11:09 PM EDT
Completed Phase 1 Interventional

Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma

NCT00002909
View directory record Official record
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
chemotherapy, oral sodium phenylbutyrate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 28, 2026, 11:09 PM EDT
Recruiting Not applicable Interventional

Group Curriculum for Improving Survivorship Outcomes in Adolescent and Young Adult Cancer Survivors

NCT05584449
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions
Counseling, Discussion, Informational Intervention, Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration
Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 39 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 28, 2026, 11:09 PM EDT
Completed Phase 1 Interventional

Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors

NCT00423865
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cisplatin, everolimus, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Oct 28, 2026, 11:09 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

NCT00923247
View directory record Official record
Conditions
Medullary Thyroid Carcinoma
Interventions
Bortezomib, Vandetanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 28, 2026, 11:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Family Quality of Life Among Families With a Member Who is a Cancer Patient

NCT00544336
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer, Solid Tumor
Interventions
questionnaire administration, survey administration, quality-of-life assessment
Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years and older
Enrollment
366 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 28, 2026, 11:09 PM EDT
Completed Phase 1 Interventional

Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors

NCT01391533
View directory record Official record
Conditions
Malignant Solid Tumors
Interventions
SAR125844
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 28, 2026, 11:09 PM EDT
Terminated Phase 1 Interventional

Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors

NCT00807755
View directory record Official record
Conditions
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Carboplatin, Etoposide, RAD001
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 28, 2026, 11:09 PM EDT
Completed Not applicable Interventional Results available

Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis

NCT01705548
View directory record Official record
Conditions
Metastatic Malignant Neoplasm to Brain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Hypofractionated Radiosurgery
Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 28, 2026, 11:09 PM EDT
Completed Phase 1 Interventional Results available

Cancer Vaccine Targeting Brachyury Protein in Tumors

NCT01519817
View directory record Official record
Conditions
Neoplasms, Malignant Solid Tumors, Colon Neoplasms, Adenocarcinoma
Interventions
GI-6301 (Yeast Brachyury Vaccine)
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 28, 2026, 11:09 PM EDT
Completed Phase 1 Interventional

PR104 and G-CSF in Treating Patients With Solid Tumors

NCT00616213
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, PR104, F-18-fluoromisonidazole
Biological · Drug · Other
Lead sponsor
Proacta, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Scottsdale, Arizona • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2011 · Synced Oct 28, 2026, 11:09 PM EDT
Terminated Phase 1 Interventional

Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

NCT02607813
View directory record Official record
Conditions
NSCLC, Ovarian Cancer, Melanoma, Other Solid Tumors
Interventions
LXH254, PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 28, 2026, 11:09 PM EDT
Completed Phase 1 Interventional

Study of XL281 in Adults With Solid Tumors

NCT00451880
View directory record Official record
Conditions
Cancer, Non-small-cell Lung Cancer, Colorectal Cancer, Papillary Thyroid Cancer, Melanoma
Interventions
XL281, famotidine
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
Scottsdale, Arizona • Tampa, Florida • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2011 · Synced Oct 28, 2026, 11:09 PM EDT
Completed Phase 1 Interventional

BMS-214662 in Treating Patients With Solid Tumors

NCT00005973
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
BMS-214662, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 28, 2026, 11:09 PM EDT
Withdrawn Phase 1 Interventional

Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

NCT01971489
View directory record Official record
Conditions
Adult Solid Neoplasm, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Buparlisib, Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Questionnaire Administration
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 28, 2026, 11:09 PM EDT
Completed Phase 1 Interventional

Fenretinide in Treating Patients With Solid Tumors

NCT00003250
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fenretinide
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
15 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 11, 2014 · Synced Oct 28, 2026, 11:09 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.

NCT04739696
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Colon Cancer, Solid Tumor, Adult
Interventions
PEPRR, Pep-Pal
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 64 Years
Enrollment
538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 28, 2026, 11:09 PM EDT
Recruiting Phase 1 Interventional

SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors

NCT07812805
View directory record Official record
Conditions
Selected Advanced Solid Tumors, Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Cancer (BTC), Gastric Cancer (GC), Esophageal Cancer (EC), Head and Neck Squamous Cell Cancer (HNSCC)
Interventions
SKL35501, SKL35502
Drug · Diagnostic Test
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Glen Burnie, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 28, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

S0916, MLN1202 in Treating Patients With Bone Metastases

NCT01015560
View directory record Official record
Conditions
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
anti-CCR2 monoclonal antibody MLN1202, polymorphism analysis, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
47
States / cities
Glendale, California • Los Angeles, California • Maywood, Illinois + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 28, 2026, 11:09 PM EDT
Terminated No phase listed Observational

Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors

NCT03061305
View directory record Official record
Conditions
Cancer, Adult Solid Tumor, Lymphoma, Multiple Myeloma
Interventions
Not listed
Lead sponsor
Strata Oncology
Industry
Eligibility
18 Years and older
Enrollment
58,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
40
States / cities
Birmingham, Alabama • Pasadena, California • Vallejo, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 28, 2026, 11:09 PM EDT
Terminated Phase 1 Interventional

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

NCT02936102
View directory record Official record
Conditions
Advanced Solid Tumors, Triple Negative Breast Cancer, Chordoma and Alveolar Soft Part Sarcoma
Interventions
FAZ053, PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 28, 2026, 11:09 PM EDT
Recruiting Phase 2 Interventional

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

NCT04165772
View directory record Official record
Conditions
Rectal Adenocarcinoma, Clinical Stage: Stage II (T3-4, N-), Stage III (Any T, N+), Solid Tumor, Solid Tumor, Adult
Interventions
TSR-042 or Dostarlimab, capecitabine or 5-FU, Intensity Modulated Radiation Therapy (IMRT)
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
10
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 28, 2026, 11:09 PM EDT